Clincosm LogoSign in Get a demo

Effect of Lugol's Solution in the Patients With Graves' Disease

Sponsor
Istanbul University (Other)
Overall Status
Completed
CT.gov ID
NCT00432146
Collaborator
(none)
36
Enrollment
12
Duration (Months)

Study Details

Study Description

Brief Summary

Context: Although some of endocrine surgeons administer Lugol's solution to decrease thyroid gland vascularity, there is still no agreement on its effectiveness.

Objective: The aims of this clinical trial are to evaluate thyroid blood flow and microvessel density in the patients with Graves' disease according to the Lugol's solution treatment preoperatively.

Design: Retrospective clinical trial. Setting: A tertiary referral center. Method: Thirty-six patients were randomly assigned to preoperative medication with Lugol's solution. Patients in group 1 (n=17) received Lugol's solution for 10 days before surgical intervention, whereas patients in group 2 (n=19) didn't receive it.

Main Outcome Measures: Blood flow through the thyroid arteries of patients with Graves' disease was measured by color flow Doppler ultrasonography. The microvessel density (MVD) was assessed immunohistochemically and Western blot analysis using the level of expression of CD-34 in thyroid tissue. The thyroid gland's weight and blood loss were measured in all patients.

Condition or Disease Intervention/Treatment Phase
  • Drug: lugol's solution

Detailed Description

Thirty-six patients were randomly assigned to preoperative medication with Lugol's solution. Patients in group 1 (n=17) received Lugol's solution for 10 days before surgical intervention, whereas patients in group 2 (n=19) didn't receive it. Blood flow through the thyroid arteries of patients with Graves' disease was measured by color flow Doppler ultrasonography. The microvessel density (MVD) was assessed immunohistochemically and Western blot analysis using the level of expression of CD-34 in thyroid tissue. The thyroid gland's weight and blood loss were measured in all patients.

Study Design

Study Type:
Observational
Time Perspective:
Prospective
Official Title:
Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease
Study Start Date :
Sep 1, 2005
Study Completion Date :
Sep 1, 2006

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    14 Years to 61 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Graves disease
    Exclusion Criteria:

    • Anticoagulant usage,

    • Previous thyroid operation,

    • Refused to participate in this study.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Istanbul University

    Investigators

    • Study Director: yesim erbil, Istanbul University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00432146
    Other Study ID Numbers:
    • 2005/117
    First Posted:
    Feb 7, 2007
    Last Update Posted:
    Oct 20, 2008
    Last Verified:
    Feb 1, 2007
    Keywords provided by , ,
    Graves' disease, Lugol's solution
    Additional relevant MeSH terms:
    Graves Disease
    Lugol's solution

    Study Results

    No Results Posted as of Oct 20, 2008